79490 Federal Register / Vol. 85, No. 238 / Thursday, December 10, 2020 / Notices 

NOTICE OF INTENT TO TERMINATE RECEIVERSHIPS

Fund Receivership name City State 

Date of 

appointment of 

receiver 

10311 .. Copper Star Bank ................................................................................. Scottsdale ..................................... AZ ....... 11/12/2010 

10313 .. Tifton Banking Company ...................................................................... Tifton ............................................. GA ....... 11/12/2010 

10319 .. Appalachian Community Bank ............................................................. McCaysville ................................... GA ....... 12/17/2010 

10353 .. Bartow County Bank ............................................................................. Cartersville .................................... GA ....... 04/15/2011 

10371 .. McIntosh State Bank ............................................................................ Jackson ......................................... GA ....... 06/17/2011 

10377 .. High Trust Bank .................................................................................... Stockbridge ................................... GA ....... 07/15/2011 

10426 .. Central Bank of Georgia ....................................................................... Ellaville .......................................... GA ....... 02/24/2012 

10476 .. Douglas County Bank ........................................................................... Douglasville ................................... GA ....... 04/26/2013 

The liquidation of the assets for each 

receivership has been completed. To the 

extent permitted by available funds and 

in accordance with law, the Receiver 

will be making a final dividend 

payment to proven creditors. 

Based upon the foregoing, the 

Receiver has determined that the 

continued existence of the receiverships 

will serve no useful purpose. 

Consequently, notice is given that the 

receiverships shall be terminated, to be 

effective no sooner than thirty days after 

the date of this notice. If any person 

wishes to comment concerning the 

termination of any of the receiverships, 

such comment must be made in writing, 

identify the receivership to which the 

comment pertains, and be sent within 

thirty days of the date of this notice to: 

Federal Deposit Insurance Corporation, 

Division of Resolutions and 

Receiverships, Attention: Receivership 

Oversight Department 34.6, 1601 Bryan 

Street, Dallas, TX 75201. 

No comments concerning the 

termination of the above-mentioned 

receiverships will be considered which 

are not sent within this time frame. 

Authority: 12 U.S.C. 1819 

Federal Deposit Insurance Corporation. 

Dated at Washington, DC, on December 4, 

2020. 

James P. Sheesley, 

Assistant Executive Secretary. 

[FR Doc. 2020–27066 Filed 12–9–20; 8:45 am] 

BILLING CODE 6714–01–P 

FEDERAL DEPOSIT INSURANCE 

CORPORATION 

FDIC Advisory Committee on 

Economic Inclusion; Notice of Charter 

Renewal 

AGENCY: Federal Deposit Insurance 

Corporation (FDIC). 

ACTION: Notice of renewal. 

SUMMARY: Pursuant to the provisions of 

the Federal Advisory Committee Act 

(‘‘FACA’’), and after consultation with 

the General Services Administration, 

the Chairman of the Federal Deposit 

Insurance Corporation has determined 

that renewal of the FDIC Advisory 

Committee on Economic Inclusion (‘‘the 

Committee’’) is in the public interest in 

connection with the performance of 

duties imposed upon the FDIC by law. 

The Committee has been a successful 

undertaking by the FDIC and has 

provided valuable feedback to the 

agency on important initiatives focused 

on expanding access to banking services 

for underserved populations. The 

Committee will continue to provide 

advice and recommendations on 

initiatives to expand access to banking 

services for underserved populations. 

The Committee will continue to review 

various issues that may include, but not 

be limited to, basic retail financial 

services such as low-cost, sustainable 

transaction accounts, savings accounts, 

small dollar lending, prepaid cards, 

money orders, remittances, the use of 

new technologies, and other services to 

promote access to the mainstream 

banking system, asset accumulation, 

and financial stability. The structure 

and responsibilities of the Committee 

are unchanged from when it was 

originally established in November 

2006. The Committee will continue to 

operate in accordance with the 

provisions of the Federal Advisory 

Committee Act. 

FOR FURTHER INFORMATION CONTACT: Mr. 

Robert E. Feldman, Committee 

Management Officer of the FDIC, at 

(202) 898–7043. 

Dated: December 3, 2020. 

Federal Deposit Insurance Corporation. 

James P. Sheesley, 

Assistant Executive Secretary. 

[FR Doc. 2020–27108 Filed 12–9–20; 8:45 am] 

BILLING CODE 6714–01–P 

FEDERAL MARITIME COMMISSION 

Notice of Agreements Filed 

The Commission hereby gives notice 

of the filing of the following agreements 

under the Shipping Act of 1984. 

Interested parties may submit 

comments, relevant information, or 

documents regarding the agreements to 

the Secretary by email at Secretary@

fmc.gov, or by mail, Federal Maritime 

Commission, Washington, DC 20573. 

Comments will be most helpful to the 

Commission if received within 12 days 

of the date this notice appears in the 

Federal Register. Copies of agreements 

are available through the Commission’s 

website (www.fmc.gov) or by contacting 

the Office of Agreements at (202) 523– 

5793 or tradeanalysis@fmc.gov. 

Agreement No.: 011550–020. 

Agreement Name: ABC Discussion 

Agreement. 

Parties: King Ocean Services Limited, 

Inc. and Seaboard Marine Ltd. 

Filing Party: Wayne Rohde; Cozen 

O’Connor. 

Synopsis: The amendment deletes 

Crowley Caribbean Services LLC as a 

party to the agreement. 

Proposed Effective Date: 11/30/2020. 

Location: https://www2.fmc.gov/ 

FMC.Agreements.Web/Public/ 

AgreementHistory/883. 

Agreement No.: 201349–001. 

Agreement Name: World Shipping 

Council Agreement. 

Parties: COSCO SHIPPING Lines Co., 

Ltd., Orient Overseas Container Line 

Ltd., and OOCL (Europe) Limited 

(acting as a single party); CMA CGM 

S.A., APL Co. Pte. Ltd., American 

President Lines, LLC, and ANL 

Singapore Pte. Ltd. (acting as a single 

party); Crowley Caribbean Services LLC 

and Crowley Latin America Services, 

LLC (acting as a single party); Evergreen 

Marine Corporation (Taiwan) Ltd.; 

Hapag-Lloyd AG; HMM Company 

Limited; Independent Container Line, 

Ltd.; Kawasaki Kisen Kaisha Ltd.; 

Maersk A/S and Hamburg Sud (acting as 

a single party); MSC Mediterranean 

Shipping Company S.A.; Mitsui O.S.K. 

Lines Ltd.; Nippon Yusen Kaisha; Ocean 

Network Express Pte. Ltd.; Wallenius 

Wilhelmsen Ocean AS; Wan Hai Lines 

Ltd. and Wan Hai Lines (Singapore) Pte. 

Ltd. (acting as a single party); Yang 


jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 85, No. 238 / Thursday, December 10, 2020 / Notices 79491 

Ming Marine Transport Corp.; Zim 

Integrated Shipping Services, Ltd.; and 

Matson Navigation Company, Inc. 

Filing Party: Robert Magovern; Cozen 

O’Connor. 

Synopsis: The Amendment adds 

Matson Navigation Company, Inc. as a 

party to the Agreement. 

Proposed Effective Date: 1/15/2021. 

Location: https://www2.fmc.gov/ 

FMC.Agreements.Web/Public/ 

AgreementHistory/34503. 

Dated: December 4, 2020. 

Rachel E. Dickon, 

Secretary. 

[FR Doc. 2020–27067 Filed 12–9–20; 8:45 am] 

BILLING CODE 6730–02–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2020–N–2196] 

Allergan Pharmaceuticals 

International, Ltd.; Withdrawal of 

Approval of a New Drug Application for 

ASACOL (Mesalamine) DelayedRelease Tablets, 400 Milligrams 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is withdrawing 

the approval of the new drug 

application (NDA) for ASACOL 

(mesalamine) delayed-release tablets, 

400 milligrams (mg), held by Allergan 

Pharmaceuticals International, Ltd., c/o 

Allergan Sales, LLC, 2525 Dupont Dr., 

Irvine, CA 92612 (Allergan). Pursuant to 

FDA’s request, Allergan agreed to 

withdrawal of this application and has 

waived its opportunity for a hearing. 

DATES: Approval is withdrawn as of 

December 10, 2020. 

FOR FURTHER INFORMATION CONTACT: 

Kimberly Lehrfeld, Center for Drug 

Evaluation and Research, Food and 

Drug Administration, 10903 New 

Hampshire Ave., Bldg. 51, Rm. 6226, 

Silver Spring, MD 20993–0002, 301– 

796–3137, Kimberly.Lehrfeld@

fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: On 

January 31, 1992, FDA approved NDA 

019651 for ASACOL (mesalamine) 

delayed-release tablets, 400 mg. It is 

approved for the treatment of mildly to 

moderately active ulcerative colitis (UC) 

in patients 5 years of age and older, and 

for the maintenance of remission of 

mildly to moderately active UC in 

adults. In December 2012, FDA 

published the guidance for industry 

‘‘Limiting the Use of Certain Phthalates 

as Excipients in CDER-Regulated 

Products,’’ available at https:// 

www.fda.gov/media/83029/download, 

describing evidence that certain 

phthalate esters (phthalates), including 

dibutyl phthalate (DBP) and di(2- 

ethylhexyl) phthalate from 

pharmaceutical products, are 

developmental and reproductive 

toxicants in laboratory animals. This 

evidence has raised concerns about 

human exposure to phthalates, 

particularly in vulnerable populations 

such as pregnant women and infants. 

ASACOL (mesalamine) delayed-release 

tablets, 400 mg, contain DBP as an 

inactive ingredient. On September 6, 

2017, FDA notified Allergen that 

because ASACOL (mesalamine) 

delayed-release tablets, 400 mg, 

contains DBP, the product presents a 

potential problem that is sufficiently 

serious to warrant withdrawal of 

approval. On December 22, 2017, 

Allergan agreed to have FDA withdraw 

approval of NDA 019651 for ASACOL 

(mesalamine) delayed-release tablets, 

400 mg, under § 314.150(d) (21 CFR 

314.150(d)) and waived its opportunity 

for a hearing. 

For the reasons discussed above, and 

pursuant to the applicant’s agreement, 

approval of NDA 019651 for ASACOL 

(mesalamine) delayed-release tablets, 

400 mg, and all amendments and 

supplements thereto, is withdrawn 

under § 314.150(d). 

Distribution of ASACOL (mesalamine) 

delayed-release tablets, 400 mg, into 

interstate commerce without an 

approved application is illegal and 

subject to regulatory action (see sections 

505(a) and 301(d) of the Federal Food, 

Drug, and Cosmetic Act (21 U.S.C. 

355(a) and 331(d)). 

Dated: December 4, 2020. 

Lauren K. Roth, 

Acting Principal Associate Commissioner for 

Policy. 

[FR Doc. 2020–27082 Filed 12–9–20; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2020–N–2227] 

Food and Drug Administration Fiscal 

Year 2020 Performance Review Board 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing the 

names of the members who will serve 

on its fiscal year (FY) 2020 Performance 

Review Board (PRB). The purpose of the 

PRB is to provide fair and impartial 

review of Senior Executive Service 

(SES), Senior Professional, 21st Century 

Cures Act, and Title 42(f) (SES 

Equivalents) performance appraisals, 

bonus recommendations, and pay 

adjustments. 

DATES: Approved October 1, 2020. 

FOR FURTHER INFORMATION CONTACT: Abu 

Sesay, Office of Human Capital 

Management (OHCM), Three White 

Flint North, 02C47, 11601 Landsdown 

St., North Bethesda, MD 20852, Office 

Number: 240–402–0440 (not a toll-free 

number). 

SUPPLEMENTARY INFORMATION: This 

action is being taken pursuant to 5 

U.S.C. 4314(c)(4), which requires that 

members of performance review boards 

be appointed in a manner to ensure 

consistency, stability, and objectivity in 

performance appraisals and requires 

that notice of the appointment of an 

individual to serve as a member be 

published in the Federal Register. 

The following persons will serve on 

the FDA FY 2020 Performance Review 

Board, which oversees the evaluation of 

performance appraisals of FDA’s Senior 

Executives and Equivalents: 

• James Sigg, PRB Chair 

• Tania Tse, PRB Officiator 

• Glenda Barfell 

• Janelle Barth 

• Vincent Bunning 

• Mary Beth Clarke 

• Elizabeth Dickinson 

• Tracey Forfa 

• Denise Huttenlocker 

• Diane Maloney 

• William Tootle 

Dated: December 4, 2020. 

Lauren K. Roth, 

Acting Principal Associate Commissioner for 

Policy. 

[FR Doc. 2020–27123 Filed 12–9–20; 8:45 am] 

BILLING CODE 4164–01–P 


jbell on DSKJLSW7X2PROD with NOTICES